Mersey and West Lancashire
Teaching Hospitals
NHS Trust

Ref. No:	2719
Date:	27/07/26
Subject:	Ophthalmology Use of Kenalog (Triamcinolone)

REQUEST

Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department:

1. The number of Kenalog administrations carried out in Ophthalmology for each of the last three financial years.

2. A breakdown of the clinical indications recorded for Kenalog use in Ophthalmology (e.g., uveitis, macular oedema, post-operative inflammation), if available.

3. Any local guidelines, protocols, or clinical policies governing the use of Kenalog in Ophthalmology.

4. Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology during the same period.

5. The number of vials issued by pharmacy to Ophthalmology for Kenalog in each of the last three financial years, if held.

6. Whether Kenalog (triamcinolone) is listed on the Trust's formulary for Ophthalmology, and if so, any restrictions or criteria for its use.

7. As Kenalog has been withdrawn from the UK market, please provide any recorded information, internal communications, policies, or decisions relating to:

8. Whether the Ophthalmology department is continuing to use existing stock,

9. Any plans or decisions to discontinue its use

10. Any identified or recommended alternative treatments.

RESPONSE

This medication is not used in the Ophthalmology department at this Trust.